In a development that underscores the challenges of expanding beyond its blockbuster obesity and diabetes portfolio, Danish pharmaceutical giant Novo Nordisk said on Monday it is terminating two further clinical trials of its experimental cardiovascular drug, ziltivekimab. The decision follows a July late‑stage study that failed to show a reduction in major adverse cardiovascular events compared with placebo.
Why the trials were stopped
Both of the newly halted studies were designed to evaluate different outcomes in patients with heart failure. An independent data monitoring committee reviewed interim data and concluded there was a “low likelihood” that either trial would produce results different from the earlier failed study. Novo Nordisk’s spokesperson confirmed the company acted promptly to cease the trials ahead of schedule.
Impact on Novo Nordisk’s pipeline
The setback comes at a time when the company is seeking to diversify its revenue streams. While its obesity drug semaglutide and diabetes treatments continue to generate strong sales, the failure of ziltivekimab highlights the difficulty of translating the inflammatory‑disease hypothesis into effective cardiovascular therapies. A similar disappointment was recently reported by Novartis, whose own experimental cardiovascular drug also failed to lower the risk of death, heart attack, or stroke in a late‑stage trial.
What remains in the pipeline
Despite the two cancellations, Novo Nordisk said one trial of ziltivekimab in patients recovering from a heart attack will proceed as planned, with results expected in the first half of 2027. The company emphasized its commitment to continue exploring innovative treatments for cardiovascular disease, even as it refocuses resources on areas with clearer pathways to success.
Broader industry context
The pharmaceutical sector has seen a string of high‑profile cardiovascular failures in recent months, prompting analysts to question whether the inflammatory‑disease approach can deliver the hoped‑for breakthroughs. Investors have responded with caution, and the market has reflected heightened scrutiny of drug pipelines that rely on novel mechanisms of action.
What this means for patients and investors
For patients, the news serves as a reminder that drug development is a lengthy and uncertain process. While the promise of new therapies remains, not every candidate will reach the market. Investors in Novo Nordisk may see short‑term volatility, but the company’s core products continue to drive robust earnings, and its long‑term strategy still includes expanding into new therapeutic areas.
Overall, the decision to halt the two heart‑failure studies illustrates Novo Nordisk’s willingness to cut losses when data suggest limited upside, allowing the firm to allocate capital toward more promising projects and maintain its leadership in obesity and diabetes care.
Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.
